

Subject Index

- A**
 Action potentials, CORT effects on, 102
 Activator protein-2, 271
 Adenine nucleotide carrier, 229
 Adrenal steroid receptor, type I and type II, 139
 Adrenal weight, aged rats and, 325
 Adrenalectomized pups, ACTH concentrations in, 283
 Adrenalectomy
 GR and MR mRNA levels and, 247
 long-term, change in dentate gyrus after, 187
 RU 38486 and RU 28318 and, 418
 spatial memory impaired by, 405
 Adrenocortical responses to ACTH, aging and, 328
 Adrenocorticotropin hormone
 corticosterone feedback and, 26
 corticosterone levels and, 16-17
 human aging and, 327
 Adrenocorticotropin hormone release, central nucleus of amygdala and, 438
 Adrenocorticotropin hormone response
 feeding and, 280
 handling and, 289
 Affective disorder, HPA system in, 345
 Affinity, GC resistance and, 375
 Age, cellular immune competence and, 207
 Age-related hippocampal neurodegeneration, 308
 Aged brain, localization of GR in, 52
 Aging
 definition of, 335
 HPA axis and, 327
 responses of GC-regulated mRNAs during, 149
 Alcohol, CD4+CD62L+ cell homing and, 421
 Aldosterone
 MRs activated by, 1
 nerve growth factor promoter activity and, 199
 spatial memory and, 405
 Aldosterone as antagonist, 65
 Alzheimer-type dementia, HPA axis and, 336
 Amitriptyline, HPA axis and, 449
 d-Amphetamine
 locomotor response to, 394
 transgenic mouse model and, 389
 Amygdala, HPA stress response and, 438
 Antagonist activity of steroid ligands, 82
 Anterior pituitary responses to direct stimulation, aging and, 328
 Antidepressant drugs, CR concentrations and, 97, 99
 Antidepressant treatment, HPA axis and, 449
 Antiinflammatory actions, glucocorticoids and, 116
 Antisense RNA, 89
 Apomorphine responsiveness, 292
 Apomorphine-susceptible rats, high level of MR in, 20
 Apoptosis, 137, 142-144
 DEX and, 470
 shrinkage step in, 221
 Arcuate nucleus, GR positive cells in, 62
 2-Aryl-3-indolacetamide derivatives (FGIN-1), 229-230
 2-Aryl-3-indolacetamides, 228
 Astrocyte cultures, sodium channel expression in, 480
 Astrocytes, GR and MR expression in, 248
 AtT20 cells, 178
 calcineurin activity in, 453
 electrically permeabilized, 456
 Arginine vasopressin hormone, Lewis rats and, 41
- B**
 Bacterial expression, MR and GR, 69
 Basal cortisol levels
 circadian regulation of, 378
 DEX suppression test and, 338, 344
 BDNF, glucocorticoids and, 196

Behavior

- MR and regulation of, 21
- MR function after high exogenous corticosterone and, 12-13

Binding studies, CORT and, 113

Blood pressure, MR function and, 14-15

Brain, MR in, 415

Brain steroidogenesis, 231

Bromo-deoxyuridine, long-term ADX and, 185, 193

Buffer, calcium, 322

CA neurons, calbindin and, 193

CA1, ischemic damage in, 203

CA1 pyramidal neurons, carbachol and, 460

CA3

- excitotoxicity and, 307
- neuronal atrophy and, 136

CA3 neurons, reduced GR in, 143

Calbindin

- CA neurons and, 193
- CA1 pyramidal cells and, 178

Calbindin-D28K, CORT and, 463

Calcineurin, 453

Calcium

- dysregulated intraneuronal, 308
- excitatory amino acids and, 297

Calcium influx, long-term hormonal effects and, 178

Calmodulin, DEX and, 178

cAMP, calcineurin inhibition and, 453

Carbachol, CA1 pyramidal neurons and, 460

Catecholamines, glucocorticoids and, 118

CD4 cells, DEX and, 215

CD4+CD62L+ cell homing, 422

Cellular localization of GR, glial and neuronal cells and, 46

Central nervous system, feedback control of HPA system and, 22

Chimeric receptors, transactivation properties of, 83

Chloramphenicol acetyltransferase, 473

Cholinergic neurons, GR immunoreactivity and, 62

Cholinergic responsiveness, 460

Circadian regulation, basal cortisol levels and, 378

Circadian rhythm, cortisol secretion and, 66

Citalopram, DEX suppression test and, 343

Cocaine kindling, 400

Cognitive deficits, neurosteroids and, 234

Corticosteroid action,

- neuroendocrine-immune interactions and, 33

Corticosteroid hormones, signal specificity and, 1

Corticosteroid receptor-responsive gene products, 254

Corticosteroid receptors

- heteronomic structure of, 68
- number of, 66
- RU 38486 and RU 28318 and, 418
- sex differences and, 431

Corticosteroid response, binary, 79

Corticosteroids

- HPA axis and, 22
- stress and, 165

Corticosterone

- behavioral changes and, 112
- calbindin-D28K mRNA and, 463
- dopamine and, 467
- fear and, 392
- locomotor response to amphetamine by, 394
- nerve growth factor mRNA levels and, 197
- nitric oxide-mediated rapid locomotor effects of, 398
- norepinephrine and, 467
- stress and, 164

Corticosterone as agonist, 65

Corticosterone feedback, CNS sites of, 25

Corticosterone response, handling and, 289

Corticosterone-responsive clones, 146

Cortisol, human aging and, 327

Cortisol secretion, circadian rhythms for, 66

Corticotropin-releasing hormone, depressives and, 346

Corticotropin-releasing hormone release, Lewis and Fischer rats and, 34

Colony-stimulating factor, glucocorticoids and, 118

Cyclic nucleotide response element binding protein, 271

Cycloheximide, CORT administration and, 177

Cytokine production, steroid regulation of, 204

Cytokines

- glucocorticoids and, 118
 - pituitary adrenal system and, 375
- Cytoplasmic glucocorticoid receptor, ligand and, 245

De-differentiation, neuronal, 180

- Defense mechanisms, glucocorticoids and, 115

Dendritic labelling, 258

Dentate gyrus

- amino acid transmission and, 142
- neuronal turnover in, 137
- seasonal changes in, 143

Depolarization, 456

Depression

- major, HPA axis dysfunction and, 97
- transgenic mouse model and, 388

Development

- CR and, 431
- GC administration during, 275

Dexamethasone

- ACTH and cortisol response to CRH and, 347
- ADX-induced neuronal de-differentiation and, 180
- apoptosis and, 470
- AtT20 cells and, 458
- calmodulin and, 178
- citalopram and, 343
- nerve growth factor promoter activity and, 199
- neurotensin and, 478
- transgenic mice and, 96

Dexamethasone-CRH test, negative feedback and, 359

Dexamethasone receptor, nuclear extractability of, 222

Dexamethasone suppression test

- dementia disorders and, 337
- pathological, (escapers), 338

Dehydroepiandrosterone

- concentrations of, 215
- effects of, on sleep

electroencephalogram, 355

GC vs, 206

Diazepam binding inhibitor, neurosteroid biosynthesis and, 223

Diazepam binding inhibitor promoter, rat, 225

DNA, GR gene and, 364

Dopamine

- behavior and, 16-17
- CORT and, 467
- serotonin exchanged for, 292

Dose response, MR and, 20

Double staining, 259

Downregulation, aged animals and, 312

Downregulation of GR, 216

Drugs of abuse, CD4+CD62L+ cell homing and, 421

Eicosanoids, glucocorticoids and, 119

8-OH-DPAT, social defeat and, 426

Electrophysiological recording, 166

- behavioral paradigms and, 176

Endotoxic shock, 117

Endotoxin exposure, maternal separation and, 290

Energy balance, RU 38486 and RU 28318 and, 418

Environment, novel, 398

Environmental regulation, GR development and, 260

Environments, enriched, 290

Estradiol, MR and, 434

Eukaryotic cell expression, 73

Excitability, neuronal, consequences for, 171

Excitatory amino acids

- CORT secretion and, 282
- high CORT and, 304
- hippocampus and, 297

Exploration, MR and GR blockage and, 13

Familial GC resistance, 369

Fear, CORT potentiation of, 392

Feedback, negative, DEX-CRH test and, 359

Feedback inhibition, antisense RNA and, 93, 99

Feeding, HPA axis affected by, 278

Fischer rats, 34

- aged, CORT levels in, 323

FK5060, 458

Flumazenil, 227

Fluoxetine, MR and, 131

Food intake, DEX and, 344

Fornix-fimbria

- cholinergic neurons in septum and, 194
- de-differentiated neurons and, 189

Forskolin, neurotensin and, 478

Function

- corticosteroids and control of, in HPA axis, 22
- MR and GR, 11

G-proteins, radioligand binding studies of, 107

GABA_A receptors, neurosteroids and, 231

GBS scale, 338

Gels, quantitative shift in signal density on, 178

Genes, defined, number of, 66

Genetic selection, 16-17

Glial fibrillary acidic protein, 47

- radial glial network and, 154-155

Glial fibrillary acidic protein mRNA, 149

Glial fibrillary acidic protein paradox, 156

Glial profiles in CNS, GR immunoreactive, 43

Glial-neuronal interaction, 254

Glucocorticoid action, sensitivity of

- intraneuronal calcium homeostasis to, 316

Glucocorticoid concentrations, basal, stress and, 116

Glucocorticoid cytosolic receptors, 424

Glucocorticoid endangerment of hippocampus, 294

Glucocorticoid feedback inhibition, aging and, 331

Glucocorticoid hormone, 157

Glucocorticoid hypersensitivity state, 374

Glucocorticoid hypothesis of age-related hippocampal neurodegeneration, 308

Glucocorticoid inhibition, early, of ACTH secretion, 453

Glucocorticoid receptor

- bacterial expression of, 69
- downregulation of, 216
- dysfunctional, 67
- environmental regulation and, 260
- feedback roles of, 24
- full occupancy of, 64
- heterodimers of, 88
- neurons and astrocytes and, 243
- phosphorylation of, 132

protection vs risk and, 324

regional and cellular localization of, in adult rat CNS, 42

transcriptional regulation by, 79

transgenic mouse model and, 391

type II, sodium channel expression and, 480

Glucocorticoid receptor expression, 291

psychosocial stress and, 429

Glucocorticoid receptor gene, DNA and, 364

Glucocorticoid receptor ligands, functional properties of, 80

Glucocorticoid receptor mRNA, 246

Glucocorticoid resistance, 362

Glucocorticoid-responsive genes, 244

Glucocorticoids

model of permissive and suppressive actions of, 119

MR gene and, 485

neurotrophin gene regulation and, 195

permissive effects of, 6-7

physiological regulation by, 147

stress and, 115

Glucocortin, 253

Glucose, *in vivo* activities of GC and, 305

Glucose transport, GCs and, 297

Glutamate, hippocampus and, 297, 305

Glutamine synthase, 252-253

Glycerol phosphate dehydrogenase, 253

Gonadotropin-releasing hormone gene expression, 473

Glycerol phosphate dehydrogenase, hippocampal protein synthesis and, 158

Glycerol phosphate dehydrogenase antibodies, 163

Glycerol phosphate dehydrogenase mRNA, 148

Granule neurons

- hippocampal dentate gyrus and, 183
- peroids for labeling of, 193

GREs, two, 85, 87

Handling

GR development and, 261

negative feedback and, 289

Heat shock protein

hippocampal protein synthesis and, 160

MR and GR and, 68

- Heat shock protein 90
 bacterial expression of MR and GR and,
 69
 DEX receptor and, 222
 nuclear function of, 77
- HeLa cells
 GR downregulation and, 218
 HSP90 and, 222
- Heteronomic structure, *de novo* formation
 of, 72
- Hidden regulators, HPA activity and, 277
- Hippocampal glucocorticoid receptor
 expression, 270
- Hippocampal slice, 158
- Hippocampal-frontal cortex-GR connection,
 serotonin and, 292
- Hippocampus
 apoptosis in, 470
 calbindin-D28K mRNA and, 463
 expectation and, 134
 GC endangerment of, 294
 GR gene expression and, 219
 memory and, 411-412
 MR in, 1
 serotonin and, 408
 sex differences and, 244
- HIV infection, HPA function in, 350
- Homeostasis, cellular, aging and/or
 neurodegeneration and, 149
- Hormones, physiological adaptation to,
 216
- Hydrocortisone, regional cerebral blood
 flow and, 386
- Hypertension, MR and, 415
- Hyperthermia, MR function and, 14-15
- Hypoglycemia, GC presence and, 295-296
- Hypothalamic cells, neurotensin and, 478
- Hypothalamic transplants, endogenous
 CRH and, 41
- Hypothalamic-pituitary-adrenal axis
 chronic antidepressant treatment on, 449
 corticosteroids and control of function in,
 22
 dementia disorders and, 336
 human aging and, 327
 immunoreactive GR and, 473
 Lewis and Fischer rats and, 35
- Hypothalamic-pituitary-adrenal axis
 activity, transgenic mice and, 92
- Hypothalamic-pituitary-adrenal
 axis-immune interaction, 34
- Hypothalamic-pituitary-adrenal system,
 psychiatric and neurological disorders
 and, 345
- Hypothalamus
 gonadotropin-releasing hormone and,
 473
 lipocortin 1 and, 442
- Hypoxia ischemia, 295
- I**midazopyridines, 228
- Imipramine
 HPA axis and, 449
 MR and, 131
- Immune signals, ACTH response and, 282
- Immunosuppressive actions, glucocorticoids
 and, 116
- ImuVert, 209
- In vitro* translation, gene expression in
 astrocytes and, 251
- In vitro* translation products, analysis of,
 146
- Infections, HPA axis and, 37
- Interferon- γ , glucocorticoids and, 118, 131
- Interleukin 1
 cortisol and, 131
 glucocorticoids and, 118
 nerve growth factor synthesis and, 196
- Interleukin 1 receptors, type 1 and type 2,
 131
- Interleukin 2, GCs and, 215
- Interleukin 4, DEX and, 215
- Interleukin 6, cortisol and, 131
- [3 H]Ketanserin, serotonin and, 268
- L**actating rats, corticosterone levels and,
 27
- Lewis rats, 34
- Licking contact, ACTH secretion
 suppressed by, 289
- Lidocaine kindling, 400
- Ligands, steroid, antagonist activity of, 82
- Lipocortin 1
 HPA function and, 441
 steroid feedback control and, 446
- Liver, GR gene expression and, 219
- Localization, MR and GR, 9
- Locomotor effects, nitric oxide and, 398

- Locomotor response to amphetamine,
 - CORT and, 394
- Long-term potentiation
 - adrenal steroids and, 138
 - calcium influx and, 178
- Lupus, antiinflammatory effects of steroids
 - on, 67

Mapping, GR
 quantitative, 43
 subjective, 42

- Maternal licking, neuroendocrine activity
 - and, 274
- Maternal regulation, HPA system and, 276
- Maternal separation, endotoxin exposure
 - and, 290
- Maze, radial arm, 411
- Mechanisms, GR downregulation, 217
- Mediator receptors, CORT and, 131
- Membrane binding sites, 102
- Memory and learning, MR and GR
 - blockage and, 12
- Metabolism
 - adrenal steroid, principal pathways of, 207
 - ion channels and, 177
- Metyrapone
 - corticosteroids and, 335
 - DEX-CRH test and, 360
- Midbrain raphe-hippocampus axis, neuronal
 - de-differentiation in, 180
- Mineralocorticoid gene, GC effects on, 485
- Mineralocorticoid isoforms, 77
- Mineralocorticoid ligands, functional
 - properties of, 80
- Mineralocorticoid mRNA, 246
- Mineralocorticoids
 - aldosterone and, 1
 - bacterial expression of, 69
 - behavior regulation and, 21
 - carbachol-induced depolarization and, 462
 - dose response as a function of, 20
 - feedback roles of, 23
 - fluoxetine and, 131
 - full occupancy of, 64
 - heterodimers of, 88
 - hippocampus and, 1
 - hypertension and, 415
 - imipramine and, 131

- neurons and astrocytes and, 243
- nonepithelial tissues and, 1
- permissive effects of, 6-7
- progesterone and, 434
- stress response size and, 31
- transcriptional regulation by, 79
- Mitochondrial diazepam binding inhibitor
 - receptor complex, 223, 229
- Mouse mammary tumor virus, transcription
 - and, 80
- mRNAs, GC-regulated, 146
- Multiple sclerosis, HPA function in, 350
- Mutants, 3', 78

- N**elson's syndrome, 369
- Neonatal period, localization of GR during, 51
 - Nerve growth factor, glucocorticoid
 - hormones and, 196
 - Nervous system, glucocorticoids and
 - neurotrophin gene regulation in, 195
 - Neuroactive steroids, effects of, on sleep
 - electroencephalogram, 353
 - Neurocognitive performance, Alzheimer's
 - disease and, 207
 - Neurodegeneration, responses of
 - GC-regulated mRNAs during, 149
 - Neuroendocrine-immune loop, 423
 - Neuroendocrine-immune interactions,
 - corticosteroid action and, 33
 - Neurofilament promoter, transgenic mice
 - and, 93
 - Neurogenesis, 137, 142-144
 - Neuronal atrophy, adrenal steroids and, 135
 - Neuronal profiles in CNS, GR
 - immunoreactive, 43
 - Neuronal-glial hypothesis, 187
 - Neurons, plasticity of, 188
 - Neuropeptides, neurons containing, 49
 - Neurosteroid biosynthesis, pharmacology
 - of, 223
 - Neurosteroids, cognitive deficits and, 234
 - Neurotensin, 478
 - Neurotoxicity, GC, 294
 - Nitric oxide, locomotor effects and, 398
 - Nonepithelial tissues, MR in, 1
 - Norepinephrine, CORT and, 467
 - Neurotrophin gene regulation,
 - glucocorticoids and, 195

Neurotrophin-3 mRNA levels, 200
Nuclear glucocorticoid receptor, ligand and, 245
Nuclear translocation, 132

Obesity
corticosterone levels and, 27
GC hypersensitivity and, 374

Occupancy
full

of GR, 64
of MR, 64
MR and GR, 10

Ontogeny, sex differences and, 244
Org 3770, 449
Ovariectomy, RU 38486 and RU 28318 and, 418

Paraventricular nucleus neurons,
hypophysiotrophic, 438
Parvalbumin, CORT and, 463
Patch clamp technique, 175
Peripheral benzodiazepine recognition sites, 226
Permissive and suppressive actions,
glucocorticoids and, 115
Permissive effects of corticosteroids, 6-7
U-shaped dose response and, 18
PET scanner, 385
Phosphorylation, GR and, 132
Physostigmine, stress and, 335
Pituitary gland, lipocortin 1 and, 442
Pituitary vasopressin receptor,
glucocorticoid upregulation of, 132
PK 11195, 227
Plasma-binding globulin, CORT and, 113
Plasminogen activator, glucocorticoids and, 119
Plasticity
basic, 306
receptor, aging and, 311
Plasticity of neurons
astrocytes and, 193
schematic model of, 188
Polymerase chain reaction, GR cDNA and, 365
Posttraumatic stress disorder, basal cortisol levels in, 378
Potassium conductance, 462

Pregnenolone, diazepam binding inhibitor and, 224
Pregnenolone forebrain content, 232
Pregnenolone formation, stimulation of, 230
Prenatal period, localization of GR during, 50
Primary cortisol resistance, 369
Progesterone
calcium currents and, 176
differential occupancy of MR and GR and, 8
high affinity of, for MR, 7
MR and, 434
Proliferating cell nuclear antigen, staining of neurons with, 185
Protein, 18-kd, 229
Protein phosphatase, 453
Proteolysis, spectrin, 306

R_{at}
A-C, 232
barrier bred, 325
Receptor assembly, 71
Receptor autoradiography, 104
Reference memory, hippocampus and, 411
Regional cerebral blood flow, 385
Reproductive behavior, CORT effects on, 101
Rheumatoid arthritis, antiinflammatory effects of steroids on, 67
RNA levels, age differences and, 323
RU486
ED₅₀ and K_i values of, 85
sleep and, 354
RU28362, maximal transcription activation by, 85

S-100, neuronal-glia hypothesis and, 187
Salt intake, ADX animals and, 194
Schizophrenia, regional cerebral blood flow and, 385
Seizures
cocaine and, 400
epilepticus, 295
Serotonergic neurons, brainstem and, 181
Serotonin
dopamine and, 292
environmental regulation and, 260

Serotonin (*cont.*)
in vitro experiments with, 177
 neurogenesis and, 291
 neuronal-glial hypothesis and, 187
 spatial memory and, 403
 steroid treatment and, 170
 Serotonin receptor mRNA, 408
 Serotonin receptors, number of, 66
 Sex differences
 CR and, 431
 GR and MR mRNA in hippocampus and, 245
 MR and, 434
 Shock, glucocorticoids and, 117
 Signal specificity, corticosteroid hormones and, 1
 Sleep electroencephalogram, effects of neuroactive steroids on, 353
 Social defeat, postsynaptic 5-HT_{1A} receptor function and, 426
 Sodium channel, 481
 Spatial memory
 aldosterone and, 405
 serotonin and, 403
 Spectrin, excitatory amino acids and, 298
 Spironolactone, high doses of, 32
 Stainability of neurons, 193
 Steroid feedback control, lipocortin 1 and, 446
 Steroid regulation of cytokine production, 204
 Steroid treatment, heat shock protein and, 164
 Steroids, free, in hippocampus, 7
 Streptococcal cell wall peptidoglycan polysaccharide, 41
 Stress
 chronic, transcendental meditation and, 381
 GC and, 115
 MR gene and, 485
 neuronal atrophy and, 135
 protein synthesis induced by, 164
 psychosocial, GR expression during, 429
 Stress hyporesponsive period, CORT levels in, 275
 Stress nonresponsive period, different species and, 292
 Stress response, MR importance for size of, 31
 Stress responsiveness, 384

Stressors, differential responses to, 148
 Stroking, neonatal HPA axis and, 282
 Suppression, interpretation of, 344
 Suprapituitary stimulation, aging and, 329
 Susceptibility factor, age-related, 316
 Synaptic activation, LTP and, 178

T helper cell, type 1 and type 2, cytokine responses and, 204
 Thymus, GR gene expression and, 219
 Thyroid hormones, handling and, 263
 Thyroxine, handling and, 263
 Time course
 CORT injection and, 165
 GFAP and, 155
 GPDH and, 155
 Timing, high GC levels in relation to insult and, 305
 Transcendental meditation, 381
 Transcortin, CR a site on, 113
 Transcription, 251
 Transcription regulation, MR and GR and, 79
 Transcriptional activation, structural changes in GRO mutant and, 73
 Transforming growth factor- β 1 mRNA, 149
 Transgenic mice
 CR antisense RNA, 90
 GR function in, 388
 Translocation, MR and, 245
 Transmitter responses, 169
 Transmitters, classical, neurons containing, 47
 Trauma, effects of, on HPA activity, 349
 Triiodothyronine, handling and, 263
 Two-dimensional gel electrophoresis, 251

Variability, rat populations and, 323
 Vascular dementia, HPA axis and, 336
 Vasopressin
 DEX-CRH test and, 360
 stressors and, 289
 Vasotocin, CORT vs, 110
 Voltage-dependent anionic channel, 228
 Voltage-gated currents, 167

Working memory, hippocampus and, 411

Index of Contributors

(Page numbers in *italics* represent discussion.)

- A**gnati, L. F., 42-61
 Akana, S. F., 22-31
 Akil, H., 20-21, 68-77, 77-78, 131, 143, 164
 Antoni, F., 78, 132-133, 178, 453-455, 456-459
 Attardi, B., 473-475
 Azmitia, E. C., xi, 66-67, 144, 180-193, 193-194, 202, 221
- B**aker, R., 62
 Balldin, J., 336-343
 Barden, N., 89-98, 98-100, 388-391
 Barnard, R. J. O., 453-455
 Barr, C. S., 157-163
 Beaulieu, S., 388-391
 Becker, J. T., 385-387
 Beers, 431-433
 Bhatnagar, M., 42-61
 Black, K. L., 204-215
 Blennow, K., 336-343
 Bohn, M. C., 178, 243-258, 258-259, 291
 Bohus, B., 144, 176, 426-428
 Bradbury, M. J., 22-31
 Brady, L. S., 99, 131-132
 Brâne, G., 336-343
 Brar, J. S., 385-387
 Brougher, D. S., 480-484
 Buckingham, J. C., 441-445, 446-448
 Buwalda, B., 426-428
- C**aamaño, C. A., 68-77
 Cadot, M., 394-397
 Carey, M. P., 434-437
 Castrén, E., 195-202
 Castrén, M., 195-202
 Chadi, G., 42-61
 Chandran, U. R., 473-475
 Cheney, D. L., 223-242
 Chiappelli, F., 204-215, 215, 421-425
 Chrousos, G. P., 362-374, 374-375
- Cidlowski, J. A., 67, 216-220
 Cintra, A., 42-61
 Corodimas, K. P., 392-393
 Cossarizza, A., 204-215
 Costa, E., 223-242
 Cunningham, L. A., 243-258
- D**agnault, A., 418-420
 Dallman, M. F., 6, 21, 22-31, 31-32, 64-66, 325-326
 Dalman, F. C., 68-77
 Damm, K., 79-87, 87-88
 de Kloet, E. R., xi, 7, 8-20, 20-21, 62, 65, 87-88, 99, 164-165, 259, 292, 325, 375-376, 377, 408-410, 426-428, 434-437, 470-472
 Dean, D. O., 243-258
 DeFranco, D. B., 66, 77-78, 165, 178, 473-475
 Deleo, M., 385-387
 DeRijk, R., 33-41
 Deshaies, Y., 418-420
 Diamond, D. M., 411-414
 Diehl, D., 385-387
 Diorio, J., 260-273
 Dokas, L. A., 157-163, 163-165, 177, 178
 Dulluc, J., 394-397
- E**delman, I. S., 7, 32, 63-67, 155
 Eldridge, J. C., 308-321
 Epstein, P., 143
- F**inch, C. E., 145-154
 Flower, R. J., 441-445, 446-448
 Flügg, G., 429-430
 Forgez, P., 476-479
 Franceschi, C., 204-215
 Francis, D., 260-273
 Friess, E., 345-359
 Frost, P., 421-425

Fuchs, E., 429-430
 Funder, J. W., 1-6, 6-7, 64-65, 88, 176
 Fuxe, K., 42-61, 61-63

Ganguli, R., 385-387
 Garcia, C., 421-425
 Giuliano, R., 243-258
 Glowa, J. R., 400-402
 Gold, P. W., 392-393, 400-402
 Gómez Sánchez, E. P., 415-417
 Gottfries, C. G., 336-343, 343-344
 Gould, E., 405-407
 Grasser, A., 345-359
 Gratton, A., 388-391
 Grayson, D. R., 223-242
 Guaza, 398-399
 Gubbels, D. G., 449-452
 Guidotti, A., 223-242
 Guild, S. B., 456-459
 Gustafsson, J.-Å., 42-61
 Gwirtsman, H., 421-425

Hengerer, B., 195-202
 Herman, J. P., 41, 438-440, 485-488
 Hernando, F., 453-455
 Hesén, W., 166-175, 460-462
 Holsboer, F., 79-87, 88, 345-359, 360-361
 Hornsby, C. D., 470-472
 Hussain, S., 243-258

Joëls, M., 112-113, 142-143, 166-175,
 175-177, 178-179, 460-462
 Jöhren, O., 429-430

Karl, M., 362-374
 Karlsson, I., 336-343
 Karst, H., 166-175
 Kling, M. A., 400-402
 Korf, J., 463-466
 Korneyev, A., 223-242
 Korte, S. M., 426-428
 Krueger, B. K., 480-484
 Krugers, H. J., 463-466

Landfield, P. W., xi, 62-63, 175, 193,
 308-321, 321-326
 LaRocque, S., 260-273

LeDoux, J. E., 392-393
 Lee, P., 421-425
 Leingärtner, A., 195-202
 Levengood, R. A., 378-380
 Levin, N., 22-31
 Levine, S., 21, 143-144, 156, 275-288,
 289-290
 Levitsky, D. K., 381-384
 Lhiaubet, A. M., 476-479
 Liao, B., 180-193
 Lindberg, J., 42-61
 Lindholm, 195-202, 203
 Longone, P., 223-242
 Loxley, H. D., 441-445, 446-448
 Luine, V., 403-404, 405-407

MacLean, C. R. K., 381-384
 Madoff, D., 385-387
 Mandarino, J. V., 381-384
 Manfrini, E., 204-215, 421-425
 Martidis, A., 385-387
 Martinez, C., 403-404
 McCormick, C. M., 431-433
 McEwen, B. S., 41, 64, 134-142, 142-144,
 154-155, 176, 194, 259, 403-404,
 405-407
 McFerran, B., 456-459
 Meaney, M. J., 32, 260-273, 274, 290-292
 Medema, R. M., 463-466
 Meijer, O. C., 408-410
 Mintun, M. A., 385-387
 Moore, F. L., 101-112, 112-114
 Morano, M. I., 68-77
 Mormède, P., 394-397
 Munck, A., 6, 115-130, 131-132, 155, 259

Náray-Fejes-Tóth, A., 115-130
 Nemer, M., 179
 Nichols, N. R., 145-154, 154-156, 164

O'Banion, M. K., 243-258
 O'Donnell, D., 260-273
 Oitzl, M. S., 8-20, 408-410
 Orchinik, M., 101-112

Pani, L., 223-242
 Peeters, B. W. M. M., 449-452

Pélaprat, D., 476-479
 Pert, A., 467-469
 Peskind, E. R., 327-335
 Pham, L., 421-425
 Pluznik, D., 400-402
 Post, R. M., 467-469
 Postema, F., 463-466
 Pratt, W. B., 68-77
 Prewitt, C. M., 438-440

Raskind, M. A., 327-335, 335
 Regland, B., 336-343
 Richard, D., 418-420
 Rochford, J., 388-391
 Romeo, E., 223-242
 Rose, G. M., 411-414
 Rose, J. D., 101-112
 Rostène, W., 476-479
 Rots, N. Y., 8-20
 Rousse, I., 388-391
 Rupprecht, R., 79-87

Sandi, C., 398-399
 Sapolsky, R. M., 294-304, 305-307
 Scarcériaux, V., 476-479
 Schlatter, L. K., 157-163
 Schneider, R. H., 381-384
 Schulkin, J., 392-393
 Schulte, H. M., 362-374
 Scribner, K. S., 22-31
 Sharma, S., 260-273
 Shipston, M. J., 453-455, 456-459
 Siever, L. J., 378-380
 Sloviter, R. S., 222
 Smith, M. A., 400-402
 Smythe, J. W., 260-273, 431-433
 Sternberg, E. M., 21, 33-41, 41, 67, 131
 Stratakis, C. A., 362-374
 Suemaru, S., 22-31

Tannenbaum, B., 260-273
 Taylor, A. D., 441-445, 446-448
 Teicher, M. H., 378-380
 Thoenen, H., 195-202
 Thomas, D. N., 467-469
 Tinner, B., 42-61
 Trestman, R. L., 378-380

Vaher, P., 405-407
 van den Berg, D. T. W. M., 8-20
 van der Heijden, R., 449-452
 Vanderheyden, P. M. L., 449-452
 Villegas, M., 403-404

Wadman, W. J., 166-175
 Walker, C-D., 22-31
 Wallin, A., 336-343
 Walton, K. G., 381-384
 Watson, S. J., Jr., 68-77, 156, 165, 485-488
 Waziri, R., 381-384
 Webster, J. C., 216-220
 Wenneberg, S. R., 381-384
 White, P. C., 31
 Wiedemann, K., 345-359
 Wilkinson, C. W., 327-335
 Wood, C., 66
 Woods, M. D., 456-459

Yarowsky, P. J., 480-484
 Yehuda, R., 378-380
 Young, D. A., 243-258

Zivkovich, E., 223-242